moneyheap
LEGN · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Legend Biotech Corporation American Depositary Shares (LEGN) stock moving?
LEGN rallied about 28% from 18.90 on Oct 22 to 24.29 on Nov 9, with volume rising in late October and early November. On Nov 10, the day Q3 results were released, the stock opened at 21.33, fell as low as 19.76, and closed at 20.41, down 16% on about 6.4M shares. That is roughly 2.7 times the average of about 2.35M shares over the 14 sessions shown, and the trade count of 58,282 was also the highest in the period. The results combined a 36% rise in CARVYKTI net trade sales with adjusted EPS of $0.14 versus a $0.00 estimate, but total sales of $359.5M slightly missed the $361.6M estimate. The market reacted to the sales shortfall and the rally that preceded it. Looking ahead, seven CARVYKTI and next-generation program presentations at ASH (Dec 12-15), an investor symposium appearance, and continued CARVYKTI growth are the main drivers. The company's guidance and call commentary were not available in the provided data, which limits confidence in the outlook.
News behind the analysis
- Legend Biotech Q3 2026 Earnings Call TranscriptLegend Biotech reported third-quarter 2026 financial results on Tuesday, and the earnings call transcript was published. The transcript itself was not available in the provided data, so guidance details could not be reviewed.
- Legend Biotech Reports Third Quarter 2026 Financial ResultsLegend Biotech reported unaudited Q3 2026 results and a 36% increase in CARVYKTI net trade sales versus the same period in 2025.
- Legend Biotech Q3 Adj. EPS $0.14 Beats $0.00 Estimate, Sales $359.500M Miss $361.619M EstimateAdjusted EPS of $0.14 was reported above the $0.00 estimate, while sales of $359.5M came in slightly below the $361.6M estimate.
- Legend Biotech Executive to Speak at Gabelli Funds 8th Annual Healthcare SymposiumAlan Bash, President of CARVYKTI at Legend Biotech, is scheduled to join a panel at the Gabelli Funds 8th Annual Healthcare Symposium.
- Legend Biotech Announces Multiple Abstracts Accepted for 2026 ASH Annual MeetingLegend Biotech will present new clinical and real-world CARVYKTI data and next-generation cell therapy updates at the 2026 ASH Annual Meeting, scheduled for Dec 12-15 in New Orleans.
About Legend Biotech Corporation American Depositary Shares
Legend Biotech is a cell therapy company with headquarters in New Jersey. Its only approved product is CARVYKTI, a CAR-T treatment for multiple myeloma, a blood cancer, which it sells with Johnson & Johnson's Janssen unit. In Q2 2026 the company reported its first profitable quarter, and an interim CEO was named that same quarter.
How it makes money
Most of its revenue comes from its roughly 50% share of CARVYKTI sales under its partnership with Janssen. CARVYKTI's worldwide net sales were about $657 million in Q2 2026, up about 50% from a year earlier. Legend also earns a smaller amount of license and milestone revenue, about $61 million in Q2 2026. It shares the cost of making the product, and gross margin on product sales was roughly 58%.
What usually moves LEGN
- CARVYKTI sales growth and use in earlier lines of treatment
- Competition from bispecific antibodies and other CAR-T therapies
- Manufacturing capacity and launches in new countries
- Pipeline data, such as the in vivo CAR-T candidate LB2501
- Progress toward lasting profitability and leadership changes